Skip to main content
Assets
Eli Lilly and logo
LLY.NYSE
Eli Lilly and
Health Care · Pharmaceuticals

Global pharmaceutical company developing innovative medicines for diabetes, oncology, immunology, and neuroscience including breakthrough weight-loss drugs.

HQ: United StatesListed: United States

Historical AI Opinions

Audit every published iPulse AI forecast batch and immutable historical research document for Eli Lilly and.

Historical AI Opinions

Eli Lilly and Company (LLY.NYSE) AI OPINIONS & ADVISOR ANALYSIS

Read the selected AI Advisor’s complete report, scenarios and forecast. Select Consensus for its investment thesis and a preview of advisor weights. Eligible access unlocks all 11 advisor reports and comparisons.

Updated on 11 April 2026Deep analysis 11 April 2026

PublisherRusslan Ramdowar
25 min readAudit All Past Forecasts
AI ResearcherAdvisor config deprecated
Elon Musk AI advisor icon
Gemini 3 Pro

Elon Musk AI

The Visionary Framework

Model rating

Strong Buy

5-Year Return Est.

+137.8%

Includes 0.40% annual net dividend contribution

Historical prices and published forecast

Historical prices and published forecastObserved prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.-17.86584.191.19K1.79K2.39KApr 2021Oct 2023Apr 2026Oct 2028Apr 2031Forecast starts
  • Observed price
  • Published advisor forecast
Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.
Quarterly Events ForecastPrice targets, total returns and complete scenario reasoning

Forecast prices in USD. Returns are cumulative from the forecast anchor. Swipe horizontally to read every column.

QuarterForecastTotal returnScenario
$1,005+7.0%
  • Market digests the Q1 2026 macro shock and realizes GLP-1 demand is unaffected by Hormuz or Fed dynamics.
  • Early FDA action anticipation for Orforglipron drives momentum.
  • TrumpRx fears begin to look overblown as LLY's volume growth easily offsets any marginal price concessions.
$1,055+12.4%
  • Q3 earnings demonstrate massive Zepbound resilience despite broad consumer staple weakness globally.
  • Orforglipron launch details and initial prescription ramps show unprecedented adoption.
  • Competition from Novo remains, but LLY maintains majority market share.
$1,140+21.3%
  • Retatrutide Phase 3 final data drops, confirming the 28% weight loss ceiling and MASH efficacy.
  • Wall Street analysts scramble to update DCF models, realizing the 'Triple-G' agonist obsoletes current standards of care.
  • FDA submission hype triggers a reflexivity momentum cycle.
$1,186+26.2%
  • Consolidation quarter. The stock takes a breather after the massive Q1 run-up.
  • Geopolitical noise and Warsh Fed balance-sheet tightening create broad market headwinds, but LLY's strong free cash flow provides a high floor.
$1,292+37.5%
  • Retatrutide secures FDA approval.
  • This is a formal paradigm shift. The media cycle goes nuclear on 'the end of obesity.'
  • Forward guidance is raised significantly as new insurance mandates for related cardiovascular endpoints kick in.
$1,370+45.8%
  • Manufacturing capacity from earlier $15B capex cycles starts meaningfully coming online, alleviating persistent bottlenecks.
  • Orforglipron oral pill adoption in Europe and Asia scales aggressively, bypassing Western injection hesitation.
$1,438+53.1%
  • Strong year-end 2027 earnings print. LLY proves it can manage complex supply chains even in a fragmented global trade regime.
  • Cash-burn-to-escape-velocity ratio flips entirely; the company is printing ungodly amounts of cash.
$1,481+57.7%
  • Minor margin compression fears as Novo Nordisk launches competing next-gen products.
  • The duopoly price war begins, but LLY's superior Triple-G efficacy protects its premium pricing tier.
$1,570+67.1%
  • LLY announces expanded indications for GLP-1/GIPs into neurodegenerative diseases or advanced sleep apnea, reopening the TAM expansion narrative.
  • Broad institutional accumulation as LLY cements itself as a top-3 global market cap company.
$1,633+73.8%
  • Steady execution. The Alabama and Pennsylvania plants are running at high utilization.
  • Regulatory noise from the 2028 US election cycle causes minor volatility, but the underlying business is bulletproof.
$1,715+82.5%
  • International revenue formally eclipses domestic revenue as the Orforglipron localized China manufacturing strategy pays off massively.
  • Easing global macro conditions provide a tailwind to healthcare spending ex-US.
$1,766+88.0%
  • Law of large numbers begins to exert gravitational pull. Moving a $1.3T+ stock requires monumental earnings beats.
  • Steady dividend hikes and stock buybacks provide a reliable total-return floor.
$1,837+95.5%
  • LLY releases Phase 2/3 data for the *next* generation of metabolic drugs (e.g., muscle-preserving weight loss agents).
  • The innovation flywheel proves it isn't stopping at Retatrutide.
$1,874+99.4%
  • Flat-to-up quarter. The market is fully saturated with the obesity narrative, and adoption curves shift from exponential to linear maturation.
  • Shift in investor base from hyper-growth to GARP (Growth at a Reasonable Price).
$1,949+107.4%
  • Decades of metabolic disease data confirm massive societal cost savings, leading to permanent government subsidization models across the OECD.
  • LLY is essentially a sovereign healthcare utility at this point.
$1,890+101.2%
  • The first meaningful patent cliff anxieties for earlier molecules (like Trulicity/Jardiance) overlap with generic competition entering peripheral markets.
  • A rare downside quarter as Wall Street recalibrates terminal growth rates.
$1,947+107.2%
  • LLY quickly recovers by flexing its fortress balance sheet, potentially acquiring smaller biotech firms to replenish the non-metabolic pipeline (e.g., immunology or targeted oncology).
$2,025+115.5%
  • Retatrutide reaches peak global penetration. The manufacturing bottlenecks are entirely historical footnotes.
  • Margins are fully optimized, generating massive shareholder yield.
$2,126+126.3%
  • A new decade. LLY announces a breakthrough in muscle-sparing metabolic regulation, kicking off a brand new S-curve targeting longevity and healthspan rather than just weight loss.
$2,190+133.1%
  • Maturation phase solidifies. LLY sits comfortably as a foundational mega-cap. The paradigm shift is complete; what was once a revolutionary disruption is now just the physical reality of human existence.
ADVISOR CONFIGURATION DEPRECATED

1. Investment Thesis — Base Case

LLY is a true Paradigm Shifter. The base case bridges the gap between current regulatory panic and the inevitable physical rollout of next-gen molecules. Despite the Q1 2026 macro meltdown, LLY's underlying execution velocity is flawless. Orforglipron unlocks the oral TAM, and Retatrutide secures the high-end efficacy moat.

  • The TrumpRx noise creates a 6-9 month valuation drag, but inelastic consumer demand wins out.
  • PA and AL manufacturing hubs come online, solving the supply bottleneck permanently.
  • International localized manufacturing (China) bypasses tariff wars and scales Asian adoption.
  • The 'Triple-G' agonist establishes LLY as the monopoly in MASH and severe obesity.
  • Implied market cap pushes toward $1.5T-$1.8T by 2031; entirely reasonable given the sheer physics of replacing the global metabolic disease burden with a daily pill.

2. Scenarios & Signals

2.1. Bull Case

The perfect storm of pipeline execution and macro irrelevance. If Retatrutide demonstrates functional cures for MASH and undeniable cardiovascular mortality reduction, it becomes a federally mandated standard of care, bypassing all TrumpRx pricing resistance.

  • Orforglipron scales globally with zero manufacturing hiccups.
  • The DOGE FDA cuts paradoxically lead to faster, deregulated 'fast-track' approvals for LLY's pipeline.
  • LLY effectively transitions from a reactive pharma company to a preventative human infrastructure platform, breaking the $2T market cap barrier.

2.2. Bear Case

The narrative trap snaps shut. The combination of Trump's 50% tariff threats on supply chains, global helium shortages, and aggressive TrumpRx price ceilings destroys LLY's operating leverage.

  • DOGE-driven FDA chaos delays Orforglipron and Retatrutide approvals by 18-24 months.
  • Novo Nordisk catches up with its own oral formulations, triggering a race-to-the-bottom price war.
  • A black-swan Phase 4 safety signal regarding long-term metabolic exhaustion surfaces, halting the exponential TAM expansion dead in its tracks.

2.3. Behavioral Alpha Signals

Sentiment, repricing cycle, crowd narrative, catalyst, and macro alignment.

Expected Volatility Regime

LowModerateHighExtreme

Greed and Fear Index

-100 Fear0+100 Greed
-45

Cycle Position

The reset is mostly complete and price drifts toward fair value.

EarlyAwareMomentumOvershootReversalCapit.StabilizeSTABILIZATION
Figure: Advisor position within the seven-stage market-recognition cycle. The highlighted point marks Stabilization.

What does Media Tell? (Crowd Consensus)

The noisy market is absolutely coping right now. They see LLY dropping from its Q4 2025 highs and think the GLP-1 run is cooked. The boomer consensus is hyper-fixating on the TrumpRx price controls and the DOGE-driven FDA chaos, convincing themselves that margins will compress and the pipeline will stall. Wall Street analysts are running legacy DCF models assuming the injection market is saturated, completely ignoring the physics of what an oral pill and a triple-agonist will do to the global TAM. They are pricing this like a mature pharma company, not a metabolic tech platform.

What Crowds Get Wrong? (Alpha/Value Gap)

Here is the variant perception: The market is pricing LLY as a company selling weight-loss injections in a politically hostile US environment. They are completely missing the S-curve inflection point. Orforglipron (the daily pill) eliminates the cold-chain and needle-phobia bottlenecks, expanding the TAM globally at an exponential rate. Retatrutide (the Triple-G) resets the efficacy ceiling to 28% weight loss, rendering competitors obsolete. LLY is not a drug company; they are building the base-layer operating system for human metabolism. The alpha gap exists because the street cannot model exponential TAM expansion driven by form-factor shifts.

When will Value Gap Repricing Happen? (Repricing Catalyst)

The FDA approval and commercial launch of the Orforglipron oral pill, expected mid-to-late 2026, combined with the final Phase 3 readouts for Retatrutide. When Q4 2026 / Q1 2027 earnings show the oral pill scaling globally without injection supply constraints, Wall Street will be forced to aggressively re-rate the future TAM. The Alpha Gap closes when the math becomes undeniable.

How is Asset Influenced by Macro Regime?

Mixed but ultimately bullish. Warsh's 'Sound Money' regime and steepening yield curves punish weak, cash-burning biotech, but LLY is a free-cash-flow juggernaut. While trade friction and TrumpRx add regulatory headwinds, LLY's product demand is completely inelastic. In a stagflationary, war-torn 2026, selling the cure to the global obesity epidemic is the ultimate macro-agnostic safe haven.

3. Positive & Negative Factors, Risks & Opportunities

3.1. Base-Case Forces

Near-certain positive forces

Top Drivers / Tailwinds

Structural or operating forces that support this advisor thesis. These forces are treated as part of the base case (more than 60% probability of occurrence).

Scroll to view all columns

Top Drivers / Tailwinds with asset-specific estimated impacts and thesis rationale
Driver / TailwindCategoryEst. stock-price impactEst. earnings impactWhy it matters
Orforglipron ORAL TAM ExpansionInnovation And Product+35%Not quantifiedFirst-principles fact: Injections are a physical bottleneck. Cold-chain storage is a logistical bottleneck. Orforglipron is a daily oral GLP-1 pill with zero food/water restrictions. This completely obliterates the friction of the current paradigm. You go from targeting millions in Western markets to literally a billion people globally. It’s the iPhone moment for metabolic health, and LLY has a massive head start. Absolute unit of an S-curve accelerator.
Retatrutide Triple G SupremacyInnovation And Product+25%Not quantifiedWhile Novo is out here optimizing dual-agonists, LLY built a 'Triple-G' agonist (GLP-1, GIP, Glucagon). Phase 3 data from early 2026 shows up to 28% weight loss. That is literal bariatric surgery in a vial. By directly signaling the liver to burn fat, it shifts the physics of human metabolism. This crushes the ceiling of existing therapeutics and locks down the high-end efficacy market. Completely bussin.
Manufacturing Fortress CapexCapital Allocation+18%Not quantifiedLLY is burning billions buying a future that competitors can't touch. $6B in Huntsville, $3.5B in PA, $3B in China. They are building literal cities of peptide and oral solid dosage manufacturing. This cash burn buys escape velocity. Once these factories hit full capacity by 2027-2028, the duopoly moat becomes impenetrable. You can't disrupt this market if you can't physically synthesize the molecules at global scale.
Expanded Clinical EndpointsSector And Industry+15%Not quantifiedGLP-1s aren't just vanity drugs; they are foundational operating system updates for the body. Getting approvals for cardiovascular outcomes, obstructive sleep apnea, and MASH (liver disease) forces insurance mandates. When you prove your drug reduces heart attacks and cures fatty liver, payors have to fold. This isn't just weight loss anymore; it's preventative medicine at scale.

Near-certain negative forces

Top Frictions / Headwinds

Expected frictions that can slow, cap, or damage this advisor thesis. These forces are treated as part of the base case (more than 60% probability of occurrence).

Scroll to view all columns

Top Frictions / Headwinds with asset-specific estimated impacts and thesis rationale
Friction / HeadwindCategoryEst. stock-price impactEst. earnings impactWhy it matters
Trumprx Price Control TheaterRegulatory-15%Not quantifiedThe new administration's TrumpRx initiative and Big Pharma Trio Accords are creating massive headline risk. The government wants to cap prices and force MFN-style discounts. The market is pricing this like a death blow to gross margins. It's mostly political theater, but the regulatory friction will serve as a persistent drag on multiples for the next 12-18 months. NGMI if you panic sell, but it suppresses the upside.
NOVO Nordisk RetaliationCompetitive Positioning-12%Not quantifiedNovo isn't just going to roll over and die. Their CagriSema and oral semaglutide pipelines are aggressive. While LLY has the current edge with Retatrutide, the duopoly price war will eventually compress the exorbitant margins as supply normalizes. Competition is the gravity that pulls down monopolistic S-curves.
DOGE FDA Efficiency ChaosRegulatory-10%Not quantifiedDOGE gutting the FDA administrative staff sounds great for efficiency in theory, but in practice, it creates a chaotic bottleneck for new drug applications. Delays in getting the rubber stamp for Retatrutide or Orforglipron due to understaffed review boards push back free cash flow realization. Time is money, and bureaucracy delays are a friction coefficient on the execution velocity.
Peptide Precursor / Helium ShocksOperational Efficiency-8.0%Not quantifiedThe Hormuz closure isn't just about oil; it's blowing up logistics for specialty chemicals and helium. You can't manufacture complex biologics and run heavy pharma tech without raw materials. Supply chain fragmentation adds physical friction to LLY's manufacturing rollout. If you can't get the atoms, you can't ship the product. Real-world physics > financial modeling.

3.2. Risks & Opportunities

Plausible downside scenarios

Tail Risks

Less likely downside scenarios that could materially hurt the outcome if they occur.

Scroll to view all columns

Tail risks with plausibility, asset-specific potential impact and scenario rationale
Tail scenarioChance of OccurringStock Price ImpactWhy plausible / what changes
Black SWAN Phase 4 Safety Signal10%-45%As you scale from millions to tens of millions of patients, rare statistical anomalies appear. If long-term use of Triple-G agonists shows a severe, undeniable link to gastroparesis, irreversible muscle atrophy, or thyroid cancer, the FDA pulls the emergency brake. The entire S-curve collapses overnight. High impact, low probability, but physics is unforgiving.
Emergency Compounding Authorization25%-30%If TrumpRx goes nuclear on drug prices, the administration could use executive authority to declare a 'metabolic emergency' and permanently authorize compounding pharmacies to mass-produce GLP-1 peptides at cost. This would instantly nuke LLY's pricing power and IP moat, turning a high-margin paradigm into a commoditized utility.

Plausible upside scenarios

Tail Opportunities

Less likely upside scenarios that could materially improve the outcome if they occur.

Scroll to view all columns

Tail opportunities with plausibility, asset-specific potential impact and scenario rationale
Tail scenarioChance of OccurringStock Price ImpactWhy plausible / what changes
Orforglipron Global OTC / Direct TO Consumer20%+25%If LLY leverages its massive China/US manufacturing to drop the marginal cost of the Orforglipron pill to near-zero, they could pioneer a hyper-scaled Direct-to-Consumer model, bypassing PBMs and insurance entirely for a flat monthly subscription. It would software-ize pharma margins and absolutely destroy the legacy healthcare distribution model.
Retatrutide MASH Miracle Status35%+18%If Phase 3 data for Retatrutide proves it practically reverses Metabolic Dysfunction-Associated Steatohepatitis (MASH), the TAM expands violently. MASH is a massive, untreated liver epidemic. If LLY secures a first-line treatment mandate for it, insurance resistance evaporates entirely. Total paradigm shift for hepatology.

5. References & Context

Search behavior, retained evidence, supplied context, and response token details.
Prompt Tokens: 58,567Thinking Tokens: 3,305Response Tokens: 5,163Total Tokens: 67,035
Researcher modeExternal search used

External web search was used. The immutable publication retained the search terms, but no source URLs were recorded.

Context supplied to the model

Public-safe inputs retained with this immutable forecast publication.

  1. 01

    Market data

    inmemory_base_placeholders__latest_eod_close_price_with_stats__var1

  2. 02

    Global context in this run

    Used

  3. 03

    Fundamental data in this run

    Not used

  4. 04

    Subject context

    Equity-specific subject and market context

  5. 05

    Global context

    Standard global market and cross-asset context

  6. 06

    Task framework

    Standard investment-forecast task guidelines

  7. 07
    Elon Musk AI advisor icon

    Advisor framework

    Elon Musk The Visionary

  8. 08

    Forecast output requested

    Equity Extended Investment Thesis (4 Quadrants and Alpha Asymmetry) + Pct Change Timeseries for Close Price with Rationale, (5Y Quarterly)

03

Global context snapshot

2025 Full-Year Global Market and World-Events Context

Download Archived Snapshot

Coverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31

File size
90.8K bytes
Words
12.8K words
Characters
90.8K characters

This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.

The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.

Top 3 market shifts from 2025 Full-Year Global Market and World-Events Context
Top 3 Market Shifts From FileDateStatus
DeepSeek shock and AI economics reset2025-01-27OPEN ENDED TREND
US tariff regime escalation and trade-system rupture2025-02-01ACTIVE POLICY REGIME
Federal Reserve easing cycle after a prolonged hold2025-09-17ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal ReserveUS Bureau of Labor StatisticsUS Bureau of Economic AnalysisUS TreasuryUS Energy Information AdministrationReuters WorldAssociated Press World NewsBBC World

And more sources from the retained context package.

2026 Year-to-Date Global Market Context through 2026-04-10

Download Archived Snapshot

Coverage 2026-01-01 to 2026-04-10 · Knowledge cutoff 2026-04-10

File size
73.5K bytes
Words
9.8K words
Characters
73.5K characters

This year-to-date package described the geopolitical, macroeconomic, monetary-policy, technology, trade, energy, and cross-asset developments available through the batch knowledge cutoff of 2026-04-10.

It supplied dated market and policy context, including rates, sovereign yields, equities, foreign exchange, energy, metals, and digital assets, for the forecast generation workflow.

Top 3 market shifts from 2026 Year-to-Date Global Market Context through 2026-04-10
Top 3 Market Shifts From FileDateStatus
The Iran and Strait of Hormuz conflict shocked energy markets2026-02-28STARTED AND ONGOING
U.S. monetary policy entered the Warsh transition2026-01-30STARTED AND ACTIVE POLICY TRANSITION
Agentic AI and infrastructure spending kept expanding2026-01-01OPEN ENDED

Representative Sources of the Context File

Federal ReserveU.S. Bureau of Labor StatisticsU.S. Bureau of Economic AnalysisU.S. TreasuryU.S. Energy Information AdministrationReutersAssociated PressBBC News

And more sources from the retained context package.

02

Fundamental context

annual: 0 periods; quarterly: 0 periods

Currencies cited: USD (quote USD).

Search terms retained

  1. 1."Eli Lilly" "retatrutide" phase 3 timeline
  2. 2."Eli Lilly" GLP-1 manufacturing capacity expansion 2025 2026
  3. 3."Eli Lilly" "orforglipron" phase 3 timeline

Search terms were retained, but this immutable publication does not contain source URLs for the run.

Original published forecast

Inspect the original revision and sealed receipt when a public record is available. Integrity verification is separate from forecast accuracy.

Research datasets created by iPulse AI and published by Future Edge Group FZE. Use is subject to the iPulse AI Terms of Service and applicable source rights.